- ￥1232
- LC labs
- 美国
- LC2-N-5300
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
见说明书
- 保质期：
＞1年
- 英文名：
NVP-AUY922
- 库存：
期货2-3周
- 供应商：
上海经科化学科技有限公司
- CAS号：
747412-49-3
- 规格：
5mg
供应商：上海经科化学科技有限公司
服务热线：400-0199-638
QQ:472482400(上海经科）
微信号：shjkchem
活动：消费积分可换充值卡！
本试剂(Luminespib (AUY-922, NVP-AUY922))
仅供科研实验使用,不得用于其他用途！
货 号：LC2-N-5300
名 称：Luminespib (AUY-922, NVP-AUY922)
别 名：NVP-AUY922
C A S ：747412-49-3
分子量：465.54
分子式：C26H31N3O5
纯 度：HPLC/TLC:>99%
说 明：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
文 献：NVP-AUY922 potently inhibited HSP90 with IC50 values of 7.8 nM and 21 nM, and Ki values of 9 nM and 8.2 nM for HSP90α and HSP90β, respectively. NVP-AUY922 showed a very high binding affinity to HSP90β with a Kd of 1.7 nM. NVP-AUY922 inhibited the proliferation of human tumor cells in vitro with GI50 values of approximately 2 to 40 nM, inducing G1-G2 arrest and apoptosis. Human endothelial cells were very sensitive to NVP-AUY922 with GI50s of 2.5-3.9 nM. NVP-AUY922 also exhibited potent antitumor efficacy in human tumor xenografts including BT474 breast, A2780 ovarian, U87MG glioblastoma, PC3 prostate, and WM266.4 melanoma. Eccles, S.A., et al. "NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis." Cancer Res. 68: 2850-2860 (2008). NVP-AUY922 showed impressive synergistic inhibitory effect with histone deacetylase inhibitors, melphalan, doxorubicin, NVP-LBH589 (Panobinostat), and suberoylanilide hydroxamic acid (SAHA, Vorinostat) on the growth of multiple myeloma cell lines and primary myeloma cells. Kaiser, M., et al. "Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma." Eur. J. Haematol. 84: 337-344 (2010). NVP-AUY922 potently inhibited the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM. NVP-AUY922 induced proliferative inhibition concordant with HSP70 upregulation and client protein depletion. Significant growth inhibition of BT-474 tumor and good tolerability were observed in athymic mice when NVP-AUY922 was administered once per week. Therapeutic effects were also concurrent with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels. Jensen, M.R., et al. "NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models." Breast Cancer Res. 10: R33 (2008). Prostate-specific antigen (PSA) may serve as a sensitive biomarker of Hsp90 inhibition. Oikonomopoulou, K., et al. "Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition." Clin. Biochem. 42: 1705-1712 (2009). 89Zr-bevacizumab PET was concordant with the antiangiogenic response and direct antitumor effects after NVP-AUY922 treatment. It provided a noninvasive tool to monitor tumor VEGF levels. Nagengast, W.B., et al. "89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922." J. Nucl. Med. 51: 761-767 (2010). NVP-AUY922 effectively reduces human epidermal growth factor receptor-2 (HER2), which can be monitored with 89Zr-trastuzumab PET in vivo non-invasively. It might serve as an early biomarker for HSP90 inhibition in HER2 positive metastatic breast cancer patients. Oude Munnink, T.H., et al. "89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft." Eur. J. Cancer 46: 678-684 (2010). Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 enhanced radiosensitivity in four tumor cell lines tested (A549, GaMG, HT 1080, and SNB19). Stingl, L., et al. "Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction." Br. J. Cancer 102: 1578-1591 (2010).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验jiaojiaoliu922 前些日子根据miRNA芯片结果，挑选了几个miRNA做验证。订了ABI的taqman探针，到货后做预实验，出现问题： realtime PCR的结果： 内参RNU48的cycle数在22左右；有一个miRNA的cycle数在20左右；其他几个miRNA的cycle数都在35。 预实验做了两遍，都是这种情况。 请大家帮忙分析一下情况。指点一下后面该怎么做。谢谢
P＝0.05 （双侧） r r（较大均方的自由度） n 2 2 3 4 5 6 7 8 9 10 12 15 20 30 60 00 1 799 364 899 922 937 948 957 963 969 977 985 993 1001 1010 1018 1 2 39.0 39.2 39.2 39.3 39.3 39.3 39.4 39.4 39.4 39.4 39.4 39.4 39.5 39.5 39.5 2 3 10.0 15.4 15
3.686 4.015 17 0.689 1.333 1.740 2.110 2.567 2.898 3.222 3.646 3.965 18 0.688 1.330 1.734 2.101 2.552 2.878 3.197 3.610 3.922 19 0.688 1.328 1.729 2.093 2.539 2.861 3.174 3.579 3.883 20 0.687 1.325 1.725 2.086 2.528 2.845 3.153
技术资料暂无技术资料 索取技术资料
